Mechanomers preventing viral destruction of cells can be mechanomerically selected.
At its simplest, such selection will take the form of parallel matricial mechanomeric selection: overlaying a set of parallel identical replicated random mechanomer matrices with, respectively, cytopalette cultures of as many different human cell types from as many different humans as practicable, and cultures of human microbial commensals (to avoid for example disturbing normal human gastrointestinal microflora and possibly facilitating fulminating toxic overgrowths); overlaying the human cell matrices with a solution of the virus in question; observing for regions where on the human cell matrices the cells do not die but on the microbial matrices no cells do, deaths signaled by mechanomeric indication for greatest sensitivity; extracting the random mechanomers from those regions from yet another parallel matrix; re-matriciating the mechanomers from each such region using different media to separate them; and repeating, until a specific and effective antiviral is developed.
Note that such antiviral selection is even more flexible than viral development of resistance to antivirals, since mechanomeric selection of antivirals is limited neither to starting from naturally-existing mechanomers nor to mechanomers of naturally-existing classes.
Furthermore, it will be much faster than the viral development of antiviral resistance.
No comments:
Post a Comment